45 completed, 20 unknown, 14 terminated, 12 recruiting. 107 Phase 3, 12 Phase 2.
Follow Bladder Cancer: new trials by email Literature Review of Bladder Cancer trials Research Report on Bladder Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sequential Chemotherapy Followed by Ultrahypofractionated Radiotherapy for Muscle-Invasive Bladder Cancer Transurethral Resection of Bladder Tumor, Sequential Systemic Chemotherapy, radiotherapy - Bladder Cancer, TURBT | Phase 3 | Not yet recruiting | Assiut University | 71 | 2026-12-01 | 2026-11-03 |
| BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy T-Bren, Dose level 1, T-bren, Dose level 2, Gemcitabine + Platinum Based Chemotherapy (Cisplatin or Carboplatin) - Urothelial Cancer, Metastatic Urothelial Cancer | Phase 3 | Recruiting | SystImmune Inc. | 520 | 2026-11-01 | 2026-11-10 |
| A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055) Sac-TMT, Pembrolizumab and Berahyaluronidase alfa, Cisplatin - Bladder Cancer | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 400 | 2026-10-23 | 2026-11-06 |
| Bladder-Sparing Treatment With Disitamab Vedotin and Toripalimab With or Without Pelvic Lymph Node Dissection in Bladder Cancer Disitamab Vedotin (RC48), Toripalimab, Transurethral Resection of Bladder Tumor - Bladder Urothelial Carcinoma, Muscle-invasive Bladder Cancer | Phase 2 / Phase 3 | Not yet recruiting | Tianjin Medical University Second Hospital | 114 | 2026-08-01 | 2026-08-10 |
| A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) Sacituzumab tirumotecan, Vinflunine, Docetaxel - Bladder Cancer | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 590 | 2026-04-23 | 2026-11-10 |
| A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma. Tislelizumab, Cisplatin, Gemcitabine and Trilaciclib, Tislelizumab, Cisplatin, Gemcitabine - Bladder Cancer | Phase 3 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 210 | 2025-10-01 | 2025-02-21 |
| Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma Dato-DXd, Carboplatin, Cisplatin - Urothelial Cancer, Bladder Cancer | Phase 2 / Phase 3 | Recruiting | Daiichi Sankyo | 630 | 2025-09-26 | 2026-08-20 |
| Trop2-targeted immunoPET Imaging of Solid Tumors [68Ga]Ga-NOTA-T4, [68Ga]Ga-NOTA-RT4, [18F]F-RESCA-T4 - Solid Tumor, Solid Carcinoma | Phase 2 / Phase 3 | Recruiting | RenJi Hospital | 400 | 2024-12-23 | 2026-05-29 |
| Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection Cysview, Karl Storz D-Light C Photodynamic Diagnostic (PDD) system - Bladder Cancer | Phase 3 | Recruiting | Johns Hopkins University | 200 | 2024-12-20 | 2026-11-03 |
| A Study of Surgical Techniques During Cystectomy Stent placement, Alvimopan - Bladder Cancer | Phase 3 | Recruiting | Memorial Sloan Kettering Cancer Center | 530 | 2024-11-21 | 2026-09-22 |
| A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer UGN-103 - Bladder Cancer, Urothelial Carcinoma | Phase 3 | Completed | UroGen Pharma Ltd. | 99 | 2024-08-29 | 2026-10-22 |
| Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC) Bacillus Calmette-Guerin: Strain Russian BCG-I, Bacillus Calmette-Guerin: Strain TICE - Bladder Cancer, Bladder Cancer Recurrent | Phase 3 | Recruiting | Verity Pharmaceuticals Inc. | 540 | 2024-04-24 | 2026-03-20 |
| A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside - Non Muscle Invasive Bladder Cancer, Urologic Cancer | Phase 3 | Active not recruiting | CG Oncology, Inc. | 367 | 2023-12-14 | 2026-07-01 |
| A Novel Application of 2% Lidocaine Injection for Male Rigid cycstoscopy-a Patient-blinded Randomised Trial Intraurethral lidocaine gel alone, Intraurethral lidocaine gel + lidocaine 2% injection, intraurethral lidocaine gel + liquid paraffinl - Bladder Cancer | Phase 3 | Withdrawn | Second Xiangya Hospital of Central South University | 2023-10-01 | 2024-04-24 | |
| Single-Dose Intravesical Chemotherapy After Diagnostic URS Intravesical Solution - Upper Urinary Tract Urothelial Carcinoma, Bladder Cancer | Phase 3 | Not yet recruiting | David D'Andrea | 394 | 2023-06-01 | 2023-04-12 |
| The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy (INCyst Trial) Immunonutrition - Bladder Cancer, Interstitial Cystitis | Phase 3 | Recruiting | Centre Hospitalier Universitaire Vaudois | 232 | 2023-04-10 | 2025-12-09 |
| A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) TAR-200, Cetrelimab, BCG Vesiculture - Bladder Cancer | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 1135 | 2023-03-23 | 2026-09-25 |
| Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC) FE 999326 - Bladder Cancer | Phase 3 | Active not recruiting | Ferring Pharmaceuticals | 25 | 2022-12-21 | 2026-09-02 |
| Comparative Study of Hexvix Blue Light Cystoscopy and White Light Cystoscopy in the Detection of Bladder Cancer Hexaminolevulinate Hydrochloride, Richard Wolf Photodynamic Diagnostic Equipment (PDD) system - Bladder Cancer | Phase 3 | Completed | Photocure | 158 | 2022-11-03 | 2024-10-03 |
| A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer UGN-102 - Bladder Cancer, Urothelial Carcinoma | Phase 3 | Active not recruiting | UroGen Pharma Ltd. | 240 | 2022-03-01 | 2026-05-11 |
Showing 20 of 107. Sign in to see all of them.
Urinary Bladder Neoplasms (107) · Non-Muscle Invasive Bladder Neoplasms (14) · Carcinoma, Transitional Cell (13) · Recurrence (6) · Urethral Neoplasms (5) · Carcinoma in Situ (3) · Neoplasm Metastasis (3) · Prostatic Neoplasms (3) · Ureteral Neoplasms (3) · Uterine Cervical Neoplasms (3) · Cholangiocarcinoma (2) · Colorectal Neoplasms (2) · Endometrial Neoplasms (2) · Neoplasms (2) · Ovarian Neoplasms (2)
Female Urogenital Diseases (107) · Female Urogenital Diseases and Pregnancy Complications (107) · Male Urogenital Diseases (107) · Neoplasms by Site (107) · Urogenital Diseases (107) · Urogenital Neoplasms (107) · Urologic Diseases (107) · Urinary Bladder Diseases (106) · Urologic Neoplasms (106) · Neoplasms (105) · Carcinoma (25) · Neoplasms by Histologic Type (25) · Neoplasms, Glandular and Epithelial (25) · Pathological Conditions, Signs and Symptoms (11) · Pathologic Processes (10)
Gemcitabine (17) · Cisplatin (15) · Mitomycin (13) · BCG Vaccine (11) · 5-aminolevulinic acid hexyl ester (7) · apaziquone (7) · Carboplatin (6) · Paclitaxel (6) · Doxorubicin (5) · Radiotherapy (5) · vinflunine (5) · Methotrexate (4) · Vinblastine (4) · pembrolizumab (4) · BCG Connaught (3)
Spectrum Pharmaceuticals, Inc (6) · Photocure (5) · European Organisation for Research and Treatment of Cancer - EORTC (4) · Memorial Sloan Kettering Cancer Center (4) · Merck Sharp & Dohme LLC (4) · UroGen Pharma Ltd. (4) · SWOG Cancer Research Network (3) · Alliance for Clinical Trials in Oncology (2) · Asan Medical Center (2) · Bristol-Myers Squibb (2) · CG Oncology, Inc. (2) · David D'Andrea (2) · Eastern Cooperative Oncology Group (2) · Turku University Hospital (2) · University Hospital Birmingham (2)
United States (51) · Canada (22) · United Kingdom (21) · Italy (15) · Belgium (13) · France (13) · Spain (13) · China (12) · Germany (12) · Poland (12) · Austria (11) · Australia (10) · Japan (10) · Netherlands (10) · South Korea (9)
Shanta Chawla, MD (3) · Bruce J. Roth, MD (2) · David P. Wood, MD (2) · Sandip Prasad, MD (2) · Show-Li Sun, MD (2) · Ahmed Lashin, Dr. (1) · Ahmed Mosbah, Prof. (1) · Alex W Yeung, MBBS (1) · Alexandre R Zlotta, MD, PhD, FRCSC (1) · Alvin Goh, MD (1) · Andreas Boehle, MD (1) · Anita L. Sabichi, MD (1)
PMID 11001674, PMID 16389183, PMID 29562804, PMID 33539743, PMID 11844814, PMID 15073851, PMID 1607913, PMID 16330205, PMID 16849761, PMID 17574960, PMID 18024869, PMID 18172274, PMID 18685414, PMID 18992952, PMID 19144456, PMID 19687335, PMID 19786668, PMID 20850152, PMID 21406089, PMID 21414125, PMID 21566413, PMID 22162575, PMID 22370319, PMID 22436453, PMID 22512481, PMID 23084842, PMID 23141049, PMID 23835707, PMID 23910233, PMID 23916692, PMID 24055428, PMID 24674149, PMID 25413313, PMID 25496767, PMID 25720673, PMID 26001531, PMID 26210894, PMID 26454620, PMID 26845426, PMID 27939400, PMID 28453896, PMID 29203268, PMID 29268948, PMID 29716640, PMID 29801011, PMID 29979488, PMID 30274699, PMID 31542806, PMID 33241650, PMID 33577729
U10CA032102 (3), 2017 (2), 2018 (2), 2023 (2), 2014 (1), P30CA008748 (1)